Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cance

5 days ago

Xilio Therapeutics (XLO, Financial) to present updated Phase 2 data for vilastobart at ASCO 2025.
The trial investigates a combination therapy for metastatic microsatellite stable colorectal cancer (MSS CRC).
Data presentation scheduled for May 31, 2025, in Chicago, Illinois.

Xilio Therapeutics, Inc. (XLO) has announced its plan to present updated data from its ongoing Phase 2 clinical trial for vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody. This presentation is part of the upcoming 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

The focus of this trial is the efficacy of vilastobart when used in combination with atezolizumab (Tecentriq®) in patients suffering from metastatic microsatellite stable colorectal cancer (MSS CRC). The presentation detailing these findings is scheduled for Saturday, May 31, 2025, from 9:00 a.m. to 12:00 p.m. CDT, during the Gastrointestinal Cancer - Colorectal and Anal poster session.

The Abstract ID for this presentation is 3553, and it will be displayed on Poster Board 222 at the conference. This event is expected to offer significant insights into the potential benefits and advancements of the vilastobart-atezolizumab combination therapy, as Xilio continues to explore novel approaches to cancer treatment.

Disclosures

I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.